These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1152 related items for PubMed ID: 11849788

  • 21. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
    Kestin LL, Goldstein NS, Vicini FA, Martinez AA.
    J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
    [Abstract] [Full Text] [Related]

  • 22. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S.
    Cancer J Sci Am; 1999 Nov; 5(5):301-6. PubMed ID: 10526671
    [Abstract] [Full Text] [Related]

  • 23. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
    Merrick GS, Wallner KE, Galbreath RW, Butler WM, Fiano R, Orio PF, Adamovich E.
    Brachytherapy; 2015 Nov; 14(5):677-85. PubMed ID: 26051802
    [Abstract] [Full Text] [Related]

  • 24. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
    Ellis RJ, Vertocnik A, Kim E, Zhou H, Young B, Sodee B, Fu P, Beddar S, Colussi V, Spirnak JP, Dinchman KH, Resnick M, Kinsella TJ.
    Int J Radiat Oncol Biol Phys; 2003 Oct 01; 57(2):362-70. PubMed ID: 12957246
    [Abstract] [Full Text] [Related]

  • 25. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.
    Int J Radiat Oncol Biol Phys; 2000 Jul 15; 47(5):1261-6. PubMed ID: 10889379
    [Abstract] [Full Text] [Related]

  • 26. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
    Stock RG, Berkowitz J, Blacksburg SR, Stone NN.
    BJU Int; 2012 Nov 15; 110(9):1257-61. PubMed ID: 22571680
    [Abstract] [Full Text] [Related]

  • 27. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG, Stone NN.
    Brachytherapy; 2002 Nov 15; 1(1):2-10. PubMed ID: 15062181
    [Abstract] [Full Text] [Related]

  • 28. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men < or = 62 years of age.
    Merrick GS, Butler WM, Lief JH, Galbreath RW.
    Int J Radiat Oncol Biol Phys; 2001 Aug 01; 50(5):1253-7. PubMed ID: 11483336
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
    Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC.
    Int J Radiat Oncol Biol Phys; 1997 Jan 01; 37(1):31-9. PubMed ID: 9054874
    [Abstract] [Full Text] [Related]

  • 32. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.
    Int J Radiat Oncol Biol Phys; 2002 Mar 15; 52(4):888-92. PubMed ID: 11958880
    [Abstract] [Full Text] [Related]

  • 33. Prostate brachytherapy: treatment strategies.
    Stone NN, Stock RG.
    J Urol; 1999 Aug 15; 162(2):421-6. PubMed ID: 10411050
    [Abstract] [Full Text] [Related]

  • 34. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.
    Int J Radiat Oncol Biol Phys; 2000 May 01; 47(2):343-52. PubMed ID: 10802358
    [Abstract] [Full Text] [Related]

  • 35. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 36. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 37. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L.
    Int J Radiat Oncol Biol Phys; 2002 Jun 01; 53(2):282-9. PubMed ID: 12023131
    [Abstract] [Full Text] [Related]

  • 38. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.
    Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W.
    Int J Radiat Oncol Biol Phys; 2003 Dec 01; 57(5):1297-303. PubMed ID: 14630265
    [Abstract] [Full Text] [Related]

  • 39. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 40. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy.
    Kwok Y, DiBiase SJ, Amin PP, Naslund M, Sklar G, Jacobs SC.
    Int J Radiat Oncol Biol Phys; 2002 Jul 01; 53(3):588-94. PubMed ID: 12062601
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.